Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) EBIT: 2011-2025

Historic EBIT for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to -$7.8 million.

  • Aytu Biopharma's EBIT fell 61.72% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 274.71%. This contributed to the annual value of -$7.8 million for FY2025, which is 259.20% down from last year.
  • Per Aytu Biopharma's latest filing, its EBIT stood at -$7.8 million for FY2025, which was down 259.20% from -$2.2 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's EBIT ranged from a high of -$2.2 million in FY2024 and a low of -$109.9 million during FY2022.
  • For the 3-year period, Aytu Biopharma's EBIT averaged around -$9.0 million, with its median value being -$7.8 million (2025).
  • Its EBIT has fluctuated over the past 5 years, first surged by 87.23% in 2024, then slumped by 259.20% in 2025.
  • Yearly analysis of 5 years shows Aytu Biopharma's EBIT stood at -$58.9 million in 2021, then tumbled by 86.69% to -$109.9 million in 2022, then surged by 84.47% to -$17.1 million in 2023, then surged by 87.23% to -$2.2 million in 2024, then slumped by 259.20% to -$7.8 million in 2025.